Review article: acute severe ulcerative colitis – evidence‐based consensus statements
Alimentary Pharmacology & Therapeutics2016Vol. 44(2), pp. 127–144
Citations Over TimeTop 10% of 2016 papers
Jinn‐Shiun Chen, Jane M. Andrews, Viraj C. Kariyawasam, N Moran, Pav Gounder, Gary S. Collins, Alissa Walsh, Susan J. Connor, T. W. T. Lee, Cherry Koh, Jeff Chang, Sudarshan Paramsothy, Stephen Tattersall, Daniel A. Lemberg, Graham Radford‐Smith, Ian C. Lawrance, Andrew J. McLachlan, Gregory Moore, Crispin Corte, Peter Katelaris, Rupert W. Leong
Abstract
These evidenced-based consensus statements on acute severe ulcerative colitis, developed by a multidisciplinary group, provide up-to-date best practice recommendations that improve and harmonise management as well as provide auditable quality assessments.
Related Papers
- → Predicting response after infliximab salvage in acute severe ulcerative colitis(2017)51 cited
- → A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab versus early colectomy(2019)8 cited
- → The use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis(2008)34 cited
- → PMO-252 Efficacy of infliximab therapy in acute and sub-acute ulcerative colitis(2012)3 cited
- → Commentary: salvage medical therapy for acute severe colitis - ciclosporin or infliximab?(2013)2 cited